Last updated: 2026-10-14 23:56:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Xencor, Inc. (XNCR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $23.40, with a market capitalisation of $1.86B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $10.38 to $30.61. This page covers its latest market performance, valuation, price trends and company information.
$1.86B | |
$23.43 | |
$58.35 | |
$5.75 | |
$23.52 | |
1.09M | |
1.37M | |
-- | |
$30.61 | |
$10.38 | |
-- | |
-- |
Xencor, Inc. (XNCR) is trading at $23.56 in after-hours trading as of 2026-10-14 23:31:00, up 0.15% ($0.04) from the regular-session close of $23.52.
After-hours trading shows how investors are pricing XNCR after the regular session closes. The current after-hours price is near the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Xencor, Inc. (XNCR) moved from $25.63 to $23.40, representing a decline of 8.70% ($2.23).
The stock traded between $22.56 and $26.03 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.53 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 64.4%
XNCR is currently trading at $23.40, placing it 64.4% of the way from its 52-week low of $10.38 to its 52-week high of $30.61. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 260 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Xencor, Inc. (XNCR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.